Dexrazoxane is the only known agent associated with less cardiac dysfunction without reducing the oncologic efficacy of the anthracycline doxorubicin in children.
Advances in cancer treatment have greatly improved survival rates of children with cancer. However, these same chemotherapeutic or radiologic treatments may result in long-term health consequences. Anthracyclines, chemotherapeutic drugs commonly used to treat children with cancer, are known to be cardiotoxic, but the mechanism by which they induce cardiac damage is still not fully understood. A higher cumulative anthracycline dose and a younger age of diagnosis are only a few of the many risk factors that identify the children at increased risk of developing cardiotoxicity. While cardiotoxicity can develop at anytime, starting from treatment initiation and well into adulthood, identifying the best cardioprotective measures to minimize the long-term damage caused by anthracyclines in children is imperative. Dexrazoxane is the only known agent to date, that is associated with less cardiac dysfunction, without reducing the oncologic efficacy of the anthracycline doxorubicin in children. Given the serious long-term health consequences of cancer treatments on survivors of childhood cancers, it is essential to investigate new approaches to improving the safety of cancer treatments.
Harake et al. (Sun,) conducted a review in Childhood cancer survivors at risk of cardiotoxicity. Dexrazoxane was evaluated. Dexrazoxane is the only known agent associated with less cardiac dysfunction without reducing the oncologic efficacy of the anthracycline doxorubicin in children.